Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
In a recent transaction involving Avidity Biosciences, Inc. (NASDAQ:RNA), President and CEO Sarah Boyce sold a substantial number of shares. According to a Form 4 filed with the Securities and Exchange Commission, Boyce sold 31,540 shares of common stock on March 20, 2025, at a weighted-average price of $31.0578 per share, totaling approximately $979,563. The sale price was near the current trading price of $30.84, with the company commanding a market capitalization of $3.7 billion. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
The sale was part of a "sell-to-cover" transaction intended to cover tax withholding obligations associated with the vesting of 62,500 time-based restricted stock units (RSUs). These RSUs were initially granted as performance-based restricted stock units (PSUs) and converted to time-based RSUs following the achievement of a performance objective by Avidity Biosciences on September 19, 2024. Notably, analysts maintain a strong bullish stance on the stock, with price targets ranging from $48 to $96 per share.
Following the transaction, Boyce retains direct ownership of 305,871 shares. The sale was executed under a pre-arranged trading plan designed to comply with Rule 10b5-1, which allows company insiders to set up a trading plan for selling stocks they own. While the company holds more cash than debt and maintains strong liquidity with a current ratio of 15.73, investors should note that RNA is not currently profitable, with earnings expected to remain negative this year.
In other recent news, Avidity Biosciences reported positive results from its Phase 1/2 EXPLORE44 trial for the treatment of Duchenne muscular dystrophy (DMD) targeting exon 44. The trial demonstrated significant improvements in dystrophin production and other biomarkers, with favorable safety and tolerability across different dose cohorts. Citi has reiterated a Buy rating with a $70 price target, citing the trial’s promising data and the potential for future expansion into neuromuscular markets. H.C. Wainwright also reaffirmed its Buy rating with a $72 target, noting the trial’s clean safety profile and potential value addition to Avidity’s platform. BMO Capital Markets initiated coverage with an Outperform rating and a $72 target, expressing confidence in Avidity’s specialized therapeutic approach. Scotiabank (TSX:BNS) followed suit with a Sector Outperform rating and a $70 target, highlighting the potential blockbuster status of Avidity’s therapies in markets lacking approved drugs. The company is preparing for a potential U.S. launch of del-zota and plans to file a Biologics License Application by the end of 2025. These developments indicate Avidity Biosciences is on track for regulatory submissions, with potential FDA approvals anticipated in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.